Securities code: Xinxiang Tuoxin Pharmaceutical Co.Ltd(301089) securities abbreviation: Xinxiang Tuoxin Pharmaceutical Co.Ltd(301089) Announcement No.: 2022054
Xinxiang Tuoxin Pharmaceutical Co.Ltd(301089)
Announcement of resolutions of the 9th meeting of the 4th board of supervisors
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Meetings of the board of supervisors
Xinxiang Tuoxin Pharmaceutical Co.Ltd(301089) (hereinafter referred to as “the company”) the notice of the 9th meeting of the 4th board of supervisors was sent to all supervisors by telephone and e-mail on May 21, 2022. The meeting was held in the company’s conference room in the form of on-site meeting and communication on May 23, 2022. The meeting was presided over by Mr. Liu Chunhao, the chairman of the board of directors and the supervisor, and attended by Mr. Liu Jianhong, the Secretary of the board of directors and the supervisor respectively.
The convening, convening and voting of this meeting comply with the relevant provisions of the company law of the people’s Republic of China and Xinxiang Tuoxin Pharmaceutical Co.Ltd(301089) articles of Association (hereinafter referred to as the articles of association), and the meeting is legal and valid. 2、 Deliberation at the meeting of the board of supervisors
1. The proposal on changing the implementation location, implementation method and asset purchase of some raised investment projects was deliberated and adopted
The board of supervisors believes that the company’s change of the implementation location and implementation method of some raised funds investment projects is a prudent decision based on the actual situation of the project, the implementation environment and the raised funds investment plan, which is conducive to the smooth implementation of the raised funds investment projects, will not affect the normal production and operation of the company, and there is no change or disguised change of the investment direction of raised funds and other situations that damage the interests of shareholders. This matter has fulfilled the necessary decision-making procedures and complies with the provisions of relevant laws, regulations and normative documents, such as the Shenzhen Stock Exchange GEM Listing Rules (revised in December 2020), the Shenzhen Stock Exchange GEM listed companies standardized operation guidelines (revised in 2020), and the guidelines for the supervision of listed companies No. 2 – regulatory requirements for the management and use of raised funds by listed companies.
See details disclosed by the company on cninfo.com（ http://www.cn.info.com.cn. ）Announcement on changing the implementation place and mode of some raised investment projects.
Voting results: 5 in favor, 0 against and 0 abstention.
2. Deliberated and passed the proposal on foreign investment and establishment of subsidiaries
The board of supervisors believes that the company invests in the establishment of a subsidiary. After the establishment of the subsidiary, it will undertake the implementation of the “1000 t / a nucleoside series food nutrition fortifier project”. It is an important link to extend the company’s production, sales and R & D industrial chain based on the consideration of strategic planning and future overall development, and can promote the long-term development of the company. There is no disguised change in the investment direction of raised funds and no damage to the interests of all shareholders, Comply with the relevant provisions of China Securities Regulatory Commission and Shenzhen Stock Exchange.
See details disclosed by the company on cninfo.com（ http://www.cn.info.com.cn. ）Announcement on foreign investment and establishment of subsidiaries and announcement on changing the implementation subject of the project of investing in the construction of 1000 tons / year nucleoside series food nutritional fortifier with over raised funds.
Voting results: 5 in favor, 0 against and 0 abstention.
3、 Documents for future reference
1. Resolution of the 9th meeting of Xinxiang Tuoxin Pharmaceutical Co.Ltd(301089) the 4th board of supervisors
It is hereby announced.
Xinxiang Tuoxin Pharmaceutical Co.Ltd(301089) board of supervisors may 24, 2022
